AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led de-escalation after 48 hours for clinically stable patients with negative cultures
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rapid diagnostic testing and pharmacist-led de-escalation
Number of subjects: 12000
Study 37716990 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with anti-viral medications
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pneumococcal urinary antigen test
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation by 72 hours from admission
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-escalation to ESA after de-escalation
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of any antibiotic
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day in-hospital mortality
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care unit transfer after admission
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-associated C. difficile infection
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Total inpatient cost
Number of subjects: 12000
Study 37716990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital length-of-stay
Number of subjects: 12000
Study 37717001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction (volume rendering) of the chest CT
Number of subjects: 0
Study 37717001 — intervention group
Group type: COMPARATOR
Intervention: 2D reconstruction (axial, coronary, and sagittal) of the chest CT
Number of subjects: 0
Study 37717072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild sleep restriction (1.5 hours less than habitual sleep) for 6 weeks
Number of subjects: 35
Study 37717543 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) for neuroticism
Number of subjects: 406
Study 37717543 — intervention group
Group type: COMPARATOR
Intervention: Control processing in difficult situations
Number of subjects: 406
Study 37717589 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicectomy scheduled within 8 hours
Number of subjects: 1822
Study 37717589 — intervention group
Group type: COMPARATOR
Intervention: Appendicectomy scheduled within 24 hours
Number of subjects: 1822
Study 37717638 — intervention group
Group type: EXPERIMENTAL
Intervention: SHHC-2.0 intervention (24 weeks of twice-weekly experiential nutrition education and group-based physical activity classes)
Number of subjects: 182
Study 37717638 — intervention group
Group type: EXPERIMENTAL
Intervention: SHHC-2.0 intervention
Number of subjects: 182
Study 37717697 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ultrasound scan (31 weeks gestational age ±6 days)
Number of subjects: 3701
Study 37717697 — intervention group
Group type: COMPARATOR
Intervention: Late ultrasound scan (35 weeks gestational age ±6 days)
Number of subjects: 3701
Study 37717786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated proton beam radiation therapy (PBT) at dose level 1 (DL1) - 5 Gy × 5 fractions, administered on days 15 to 19 in a 28-day cycle before starting cycle 7 of mFFX.
Number of subjects: 9
Study 37717786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated proton beam radiation therapy (PBT) at dose level 2 (DL2) - 5 Gy × 5 fractions, administered on days 8 to 12 in a 21-day cycle before starting cycle 7 of mFFX.
Number of subjects: 9
Study 37717787 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Fraction Stereotactic Radiosurgery (SF-SRS)
Number of subjects: 404
Study 37717787 — intervention group
Group type: COMPARATOR
Intervention: Multifraction Stereotactic Radiosurgery (MF-SRS)
Number of subjects: 404
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider opinion baseline
Number of subjects: 984
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider opinion univariable logistic regression
Number of subjects: 984
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 984
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest classifier
Number of subjects: 984
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting
Number of subjects: 984
Study 37717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network
Number of subjects: 984
Study 37717908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-driven language intervention
Number of subjects: 95
Study 37717908 — intervention group
Group type: COMPARATOR
Intervention: Health-safety lessons (control)
Number of subjects: 95
Study 37717936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation plus supplemental oxygen for the first 48 hours
Number of subjects: 70
Study 37717936 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (control)
Number of subjects: 70
Study 37717936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation plus supplemental oxygen
Number of subjects: 70
Study 37718234 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m-mercaptoacetyltriglycine diuretic renography at timepoint 1
Number of subjects: 37
Study 37718234 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard parameters for differential renal function development
Number of subjects: 37
Study 37718234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue tracer transit
Number of subjects: 37
Study 37718392 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 931
Study 37718442 — intervention group
Group type: EXPERIMENTAL
Intervention: DeCIDE PC intervention
Number of subjects: 0
Study 37718446 — intervention group
Group type: EXPERIMENTAL
Intervention: LPB at L3 level (P group)
Number of subjects: 84
Study 37718446 — intervention group
Group type: EXPERIMENTAL
Intervention: T12 paravertebral block combined with LPB at L3 and L4 levels (TP group)
Number of subjects: 84
Study 37718446 — intervention group
Group type: EXPERIMENTAL
Intervention: LPB combined with TQLB at L3 level (PQ group)
Number of subjects: 84
Study 37718441 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D flow CMR analysis
Number of subjects: 163
Study 37718471 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2.0 mg twice daily (b.i.d.)
Number of subjects: 76
Study 37718721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegozafermin 27 mg once weekly for 20 weeks
Number of subjects: 20
Study 37718930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose Bier's block
Number of subjects: 0
Study 37718930 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 0
Study 37718932 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 1348
Study 37718932 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 1348
Study 37718932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348
Study 37718932 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (FIL200, FIL100, placebo)
Number of subjects: 1348
Study 37719091 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (500 steps/day weekly until 10,000 steps/day)
Number of subjects: 379
Study 37719091 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 379
Study 37719091 — intervention group
Group type: COMPARATOR
Intervention: Less active participants
Number of subjects: 379
Study 37719417 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination (1 intradermal dose of 0.1 mL)
Number of subjects: 84
Study 37719417 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination
Number of subjects: 84
Study 37719467 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered Spring Forest Qigong
Number of subjects: 0
Study 37719467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37719735 — intervention group
Group type: EXPERIMENTAL
Intervention: GDP per capita
Number of subjects: 205
Study 37719735 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to electricity
Number of subjects: 205
Study 37719735 — intervention group
Group type: EXPERIMENTAL
Intervention: Political stability, absence of violence/terrorism
Number of subjects: 205
Study 37719735 — intervention group
Group type: EXPERIMENTAL
Intervention: Civil liberties
Number of subjects: 205
Study 37720011 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted index case testing
Number of subjects: 26
Study 37720013 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT (5 weekly psychologist-led video tele-CBT sessions)
Number of subjects: 44
Study 37720013 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (dose-and delivery matched survivorship education)
Number of subjects: 44
Study 37720025 — intervention group
Group type: EXPERIMENTAL
Intervention: OEND intervention (naloxone distribution and overdose education)
Number of subjects: 29
Study 37720027 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20
Number of subjects: 29
Study 37720040 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-based PCR viral testing
Number of subjects: 69
Study 37720040 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) antigen testing
Number of subjects: 69
Study 37720040 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based PCR viral testing and POC testing
Number of subjects: 69
Study 37720040 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing protocols for DHCWs and patients
Number of subjects: 69
Study 37720052 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRST (transdiagnostic intervention built on five empirically supported principles of change)
Number of subjects: 212
Study 37720052 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study 37720184 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of new-onset LBBB post-TAVI
Number of subjects: 0
Study 37720185 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in ICU rounds (N = 16)
Number of subjects: 27
Study 37720185 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (N = 11)
Number of subjects: 27
Study 37720373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (MSP) supplementation
Number of subjects: 70
Study 37720373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37720456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - eight sessions of group-based CBT (every 2-3 weeks)
Number of subjects: 0
Study 37720456 — intervention group
Group type: COMPARATOR
Intervention: Usual care (usual oncology care)
Number of subjects: 0
Study 37720456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 37720495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 1274
Study 37720495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-immune-inflammation value (PIV)
Number of subjects: 1274
Study 37720540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor Augmented Pump (SAP) therapy
Number of subjects: 46
Study 37720540 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Injection (MDI) therapy
Number of subjects: 46
Study 37720564 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline treatment at 16× the MIC for 72 hours
Number of subjects: 0
Study 37720591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr) delivered via smartphone app for four weeks, including mindfulness and cognitive behavioral therapy modules.
Number of subjects: 0
Study 37720591 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 0
Study 37720591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr).
Number of subjects: 0
Study 37720695 — intervention group
Group type: EXPERIMENTAL
Intervention: Early 75 g OGTT at 12-15 weeks of gestation
Number of subjects: 829
Study 37720695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering postload glucose values (75 g OGTT cut-off values of 5.1, 8.9, and 7.8 mmol/L)
Number of subjects: 829
Study 37720924 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 1604
Study 37720924 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery (MS)
Number of subjects: 1604
Study 37720929 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural orifice specimen extraction colectomy (NC)
Number of subjects: 99
Study 37720929 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic colorectal resection (CLR)
Number of subjects: 99
Study 37721127 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP65 group (target MAP 65 mmHg)
Number of subjects: 72
Study 37721127 — intervention group
Group type: COMPARATOR
Intervention: APP60 group (target APP > 60 mmHg)
Number of subjects: 72
Study 37721127 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP65 group
Number of subjects: 72
Study 37721127 — intervention group
Group type: COMPARATOR
Intervention: APP60 group
Number of subjects: 72
Study 37721127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 37721470 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive COX-2 inhibitor etoricoxib
Number of subjects: 15
Study 37721470 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 15
Study 37721581 — intervention group
Group type: EXPERIMENTAL
Intervention: novel somatostatin receptor (SSTR) antagonist
Number of subjects: 15
Study 37721581 — intervention group
Group type: COMPARATOR
Intervention: not available
Number of subjects: 15
Study 37721703 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated phacoemulsification with IOL implantation in diabetic patients with PEX (Group 1)
Number of subjects: 61
Study 37721703 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated phacoemulsification with IOL implantation in diabetic patients (Group 2)
Number of subjects: 61
Study 37721703 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated phacoemulsification with IOL implantation in patients with PEX (Group 3)
Number of subjects: 61
Study 37721735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of after-school physical activity time outdoors on school days
Number of subjects: 2032
Study 37721735 — intervention group
Group type: COMPARATOR
Intervention: Free arrangement of after-school activity (control group)
Number of subjects: 2032
Study 37721734 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth dementia care program with an unlicensed dementia care guide providing caregiver support and education.
Number of subjects: 460
Study 37721738 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled automated LVO detection from CT angiogram with secure messaging
Number of subjects: 243
Study 37721754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab maintenance therapy after FOLFIRI plus cetuximab induction therapy
Number of subjects: 139
Study 37721754 — intervention group
Group type: COMPARATOR
Intervention: Observation after FOLFIRI plus cetuximab induction therapy
Number of subjects: 139
Study 37721786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week tele-RHB program along with CPAP therapy
Number of subjects: 50
Study 37721786 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy alone
Number of subjects: 50
Study 37721786 — intervention group
Group type: EXPERIMENTAL
Intervention: tele-RHB program and CPAP therapy
Number of subjects: 50
Study 37721790 — intervention group
Group type: EXPERIMENTAL
Intervention: Social VR training
Number of subjects: 90
Study 37721790 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional social skills training
Number of subjects: 90
Study 37721790 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study 37721790 — intervention group
Group type: EXPERIMENTAL
Intervention: Social VR training and Traditional social skills training
Number of subjects: 90
Study 37721791 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-Patch device
Number of subjects: 320
Study 37721795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL) therapy
Number of subjects: 60
Study 37721795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim Light (DL) therapy
Number of subjects: 60
Study 37721795 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study 37721952 — intervention group
Group type: COMPARATOR
Intervention: Warning labels
Number of subjects: 3518
Study 37721952 — intervention group
Group type: COMPARATOR
Intervention: Tax (30% price increase)
Number of subjects: 3518
Study 37721952 — intervention group
Group type: COMPARATOR
Intervention: Combined warning labels + tax
Number of subjects: 3518
Study 37721952 — intervention group
Group type: COMPARATOR
Intervention: Combined condition
Number of subjects: 3518
Study 37721952 — intervention group
Group type: COMPARATOR
Intervention: Tax condition
Number of subjects: 3518
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin + Albendazole (IA)
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin + Albendazole (MoxA)
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin + Diethylcarbamazine + Albendazole (IDA)
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin + Diethylcarbamazine + Albendazole (MoxDA)
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug treatments (IDA, MoxDA)
Number of subjects: 164
Study 37721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Mf counts
Number of subjects: 164
Study 37721990 — intervention group
Group type: COMPARATOR
Intervention: Oral Δ
Number of subjects: 0
Study 37721990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37722087 — intervention group
Group type: EXPERIMENTAL
Intervention: abemaciclib
Number of subjects: 237
Study 37722087 — intervention group
Group type: EXPERIMENTAL
Intervention: neratinib
Number of subjects: 237
Study 37722087 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-115
Number of subjects: 237
Study 37722087 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 237
Study 37722131 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 382
Study 37722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 382
Study 37722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hyperlipidemia
Number of subjects: 382
Study 37722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hypertension
Number of subjects: 382
Study 37722196 — intervention group
Group type: EXPERIMENTAL
Intervention: Age stratification
Number of subjects: 382
Study 37722238 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback intervention (2 sessions)
Number of subjects: 36
Study 37722238 — intervention group
Group type: COMPARATOR
Intervention: Yoked sham feedback (control group)
Number of subjects: 36
Study 37722357 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy followed by autologous stem cell transplantation
Number of subjects: 113
Study 37722354 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib + CIT (560 mg daily plus 6 cycles of BR/R-CHOP)
Number of subjects: 403
Study 37722354 — intervention group
Group type: COMPARATOR
Intervention: placebo + CIT (placebo daily plus 6 cycles of BR/R-CHOP)
Number of subjects: 403
Study 37722354 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib + CIT
Number of subjects: 403
Study 37722354 — intervention group
Group type: COMPARATOR
Intervention: placebo + CIT
Number of subjects: 403
Study 37722483 — intervention group
Group type: EXPERIMENTAL
Intervention: PolarX cryoballoon ablation
Number of subjects: 200
Study 37722483 — intervention group
Group type: COMPARATOR
Intervention: Arctic Front cryoballoon ablation
Number of subjects: 200
Study 37722482 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based home blood pressure monitoring (HBPM) with a clinical pharmacist, including pro-active outreach, provision of BP devices, automated texting, visit note template, audit and feedback, and training.
Number of subjects: 0
Study 37722482 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based home blood pressure monitoring (HBPM) with a clinical pharmacist.
Number of subjects: 0
Study 37722559 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 50
Study 37722559 — intervention group
Group type: COMPARATOR
Intervention: Standard conditions
Number of subjects: 50
Study 37722662 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated malaria-helminth treatment approach
Number of subjects: 57
Study 37722831 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 118
Study 37722831 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Number of subjects: 118
Study 37723109 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered long-acting local anaesthetic (lidocaine and bupivacaine with epinephrine)
Number of subjects: 116
Study 37723109 — intervention group
Group type: COMPARATOR
Intervention: Non-buffered long-acting local anaesthetic (lidocaine and bupivacaine with epinephrine)
Number of subjects: 116